Compare Enovix Corporation (ENVX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs IDEXX Laboratories, Inc. — how do they compare? Enovix Corporation trades at $2.45 (market cap $549.72M), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 73.5× Enovix Corporation's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 6,635,687). Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| ENVX | IDXX | |
|---|---|---|
Market Cap | $549.72M | $40.43B |
Volume | 6,635,687 | 692,164 |
Sector | Industrials | Health |
52-Week High | $13.19 | $766.68 |
52-Week Low | $2.50 | $504.70 |
Typical Hold Time | 11 Days | 46 Days |
Enterprise Value | $611.42M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.485, down 2.55% on the day, reflecting a bearish technical outlook. The company continues to post significant losses, with a net income margin of -473.89% in 2026, though quarterly earnings have consistently beaten expectations. Recent news is dominated by a sudden CEO transition, but the company reaffirmed its strategy and guidance, highlighting progress in its drone and defense battery supply chain.
The outlook is highly speculative. Analyst consensus is bullish with a $10.75 price target, but substantial execution risks and persistent cash burn pose a threat to shareholder value. Investment potential hinges on successful commercialization and achieving profitability, which remains distant.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
